United States Triple-Negative Breast Cancer KOL Interview, 2019: Prescribing Habits, Key Marketed Brands, and Late-Phase Pipeline Therapies - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 23, 2019--
The “Triple-Negative Breast Cancer KOL Interview - US” report has been added to ResearchAndMarkets.com’s offering.
A US-based key opinion leader provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple-negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed.
Key pipeline assets highlighted include:
For more information about this report visit https://www.researchandmarkets.com/r/d2kmwv
View source version on businesswire.com:https://www.businesswire.com/news/home/20191223005582/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 12/23/2019 05:03 PM/DISC: 12/23/2019 05:03 PM